Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease
暂无分享,去创建一个
A. Amin | M. Sood | C. Linde | J. Burton | C. Mellström | J. Eudicone | E. Lesén | Alaster M Allum
[1] M. Någård,et al. A Phase 1, open-label, crossover study evaluating the effect of a single dose of sodium zirconium cyclosilicate on the pharmacokinetics of tacrolimus and cyclosporin , 2022, Clinical kidney journal.
[2] 12 Impact on Hospitalizations of Long-term Versus Short-Term Sodium Zirconium Cyclosilicate Therapy During Routine Care for Patients With Hyperkalemia: RECOGNIZE I , 2022, American Journal of Kidney Diseases.
[3] C. Pollock,et al. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies , 2021, Clinical kidney journal.
[4] Kerrie L. Ford,et al. Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study , 2021, Clinical kidney journal.
[5] V. Fonseca,et al. Inpatient management and post-discharge outcomes of hyperkalemia , 2021, Hospital practice.
[6] T. Hiemstra,et al. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD) , 2021, Clinical kidney journal.
[7] E. Núñez,et al. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] Steven D. Woods,et al. Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients , 2021, Journal of medical economics.
[9] Sathish Kumar Jayapal,et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.
[10] J. Carrero,et al. Clinical Management of Hyperkalemia. , 2020, Mayo Clinic proceedings.
[11] Y. Yamasaki,et al. A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia , 2020, Clinical and Experimental Nephrology.
[12] N. Kashihara,et al. Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan , 2020, Kidney medicine.
[13] W. Qunibi,et al. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia , 2020, Expert opinion on pharmacotherapy.
[14] E. Wu,et al. Postdischarge Health Care Costs and Readmission in Patients With Hyperkalemia-Related Hospitalizations , 2020, Kidney international reports.
[15] E. Wu,et al. Prevalence and economic burden of hyperkalemia in the United States Medicare population , 2020, Current medical research and opinion.
[16] K. Kalantar-Zadeh,et al. New solutions to old problems—metabolic acidosis in chronic kidney disease , 2020, Annals of translational medicine.
[17] L. G. Vu,et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.
[18] B. Palmer. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. , 2020, Mayo Clinic proceedings.
[19] E. Lerma,et al. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE , 2019, American Journal of Nephrology.
[20] A. Sjölander,et al. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] A. Garg,et al. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. , 2019, JAMA internal medicine.
[22] J. Butler,et al. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. , 2019, Clinical journal of the American Society of Nephrology : CJASN.
[23] J. Wetmore,et al. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England , 2019, BMC Nephrology.
[24] E. Wu,et al. The Cost of Hyperkalemia in the United States , 2017, Kidney international reports.
[25] J. McDermott,et al. Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate , 2017, Drug design, development and therapy.
[26] B. Pitt,et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes , 2017, American Journal of Nephrology.
[27] K. Fitch,et al. The Clinical and Economic Burden of Hyperkalemia on Medicare and Commercial Payers. , 2017, American health & drug benefits.
[28] C. Kovesdy. Updates in hyperkalemia: Outcomes and therapeutic strategies , 2017, Reviews in Endocrine and Metabolic Disorders.
[29] S. Brunelli,et al. Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[30] N. Oestreicher,et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.
[31] M. Nuttall,et al. Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap , 2014, PloS one.
[32] M. Rolfe,et al. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[33] F. Locatelli,et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. , 1996, The New England journal of medicine.